Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00515879 · ClinicalTrials.gov registry record · Phase 3
Effect of D-cycloserine Plus Cognitive Behavioral Therapy on People With Social Phobia
A Phase 3 study, sponsored by Boston University Charles River Campus.
- Completed
- Registry status
- Phase 3
- Development phase
- 169
- Enrollment target
NCT00515879 is a Phase 3 study that has completed, run by Boston University Charles River Campus. The registered enrollment target is 169 participants.
The verdict
NCT00515879, a Phase 3 study, has completed, sponsored by Boston University Charles River Campus.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 169 participants
- Enrollment target
Study Summary
This study will assess the effectiveness of D-cycloserine combined with cognitive-behavior therapy in treating people with social anxiety disorder.
Interventions
- DRUG Placebo
- BEHAVIORAL Cognitive behavioral therapy (CBT)
- DRUG D-cycloserine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 169 participants |
| Start Date | 2007-12 |
| Est. Completion | 2011-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00515879
The ClinicalTrials.gov registry entry for NCT00515879 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 169 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston University Charles River Campus, which has 104 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00515879 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00515879 about?
NCT00515879 is a clinical study titled "Effect of D-cycloserine Plus Cognitive Behavioral Therapy on People With Social Phobia". This study will assess the effectiveness of D-cycloserine combined with cognitive-behavior therapy in treating people with social anxiety disorder.
What is the current status of trial NCT00515879?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 169 participants. The study started on 2007-12. Estimated completion is 2011-12.
What interventions are being tested in trial NCT00515879?
The interventions under investigation include: Placebo (DRUG), Cognitive behavioral therapy (CBT) (BEHAVIORAL), D-cycloserine (DRUG).
Who is sponsoring clinical trial NCT00515879?
This trial is sponsored by Boston University Charles River Campus, which has 104 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.